Quick-acting clot-busting medications called thrombolytics are not usually used unless youre in a life-threatening situation, such as a stroke, heart attack, or a large pulmonary embolism
Sheffield-Moore M, Wiktorowicz JE, Soman KV, Danesi CP, Kinsky MP, Dillon EL, Randolph KM, Casperson SL, Gore DC, Horstman AM, Lynch JP, Doucet BM, Mettler JA, Ryder JW, Ploutz-Snyder LL, Hsu JW, Jahoor F, Jennings K, White GR, McCammon SD, Durham WJ
Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, et al
Sorafenib inhibits the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1, a key negative regulator of translation controlled by mTOR (Sauzay et al., 2018), (Rosenberg et al., 2018)